Baggio Laurie L, Drucker Daniel J
J Clin Invest. 2014 Oct;124(10):4223-6. doi: 10.1172/JCI78371. Epub 2014 Sep 9.
The peptide hormone glucagon-like peptide-1 (GLP-1) enhances glucose-induced insulin secretion and inhibits both gastric emptying and glucagon secretion. GLP-1 receptor (GLP-1R) agonists control glycemia via glucose-dependent mechanisms of action and promote weight loss in obese and diabetic individuals. Nevertheless, the mechanisms and cellular targets transducing the weight loss effects remain unclear. Two recent studies in the JCI provide insight into the neurons responsible for this effect. Sisley et al. reveal that GLP-1R agonist-induced weight loss requires GLP-1Rs in the CNS, while Secher et al. reveal that a small peptide GLP-1R agonist penetrates the brain and activates a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss. Together, these two studies elucidate pathways that inform strategies coupling GLP-1R signaling to control of body weight in patients with diabetes or obesity.
肽类激素胰高血糖素样肽-1(GLP-1)可增强葡萄糖诱导的胰岛素分泌,并抑制胃排空和胰高血糖素分泌。GLP-1受体(GLP-1R)激动剂通过葡萄糖依赖性作用机制控制血糖,并促进肥胖和糖尿病个体的体重减轻。然而,介导体重减轻作用的机制和细胞靶点仍不清楚。《临床研究杂志》最近的两项研究为负责这种作用的神经元提供了见解。西斯利等人发现,GLP-1R激动剂诱导的体重减轻需要中枢神经系统中的GLP-1R,而塞舍尔等人发现,一种小肽GLP-1R激动剂可穿透大脑并激活弓状核中表达GLP-1R的神经元子集以减轻体重。这两项研究共同阐明了一些途径,这些途径为将GLP-1R信号与糖尿病或肥胖症患者的体重控制相结合的策略提供了依据。